Testing ALN-6222 in Adults With Obesity
Tests the drug ALN-6222, given as an injection, in adults with obesity.
Key facts
- Who runs it
- Alnylam Pharmaceuticals
- Where
- Mount Royal, CanadaSee the site
- Trial code
- Registry title
- A Study to Evaluate ALN-6222 in Participants With Obesity
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 88 people, planned
- Started
- 4 Jun 2026
- Expected to end
- 14 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ALN-6222
- Placebo
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity to test a new drug, ALN-6222, given as an injection under the skin. This is the first time it is given to people.
- Age
- 18 Years to 65 Years
- Sex
- All sexes can join.
- Disease stage
- Body mass index of 30 kg/m^2 or more and less than 40 kg/m^2. Hemoglobin A1c below 6.5% (48 mmol/mol).
Main reasons for not taking part
- Liver tests (ALT or AST) more than 1.5 times the upper limit of normal
- Known HIV infection
- Known current or chronic hepatitis C or hepatitis B infection
- Kidney function (eGFR) below 60 mL/min/1.73m^2 at screening
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Is an adult patient with a body mass index ≥30 kg/m\^2 to <40 kg/m\^2
- Has a hemoglobin A1c <6.5%
Who cannot take part
- Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN)
- Has an estimated glomerular filtration (eGFR) of <60 mL/min/1.73m\^2 at screening; Note: other protocol defined inclusion / exclusion criteria apply
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in Canada
- Mount RoyalHospital not named in the registryTaking people
About the trial
What the trial wants to find out
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
The 2 groups in the trial
- ALN-6222Treatment being tested
Participants will be administered a single dose of ALN-6222.
- PlaceboPlacebo, for comparison
Participants will be administered a single dose of placebo.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ALN-6222 in Adult Participants With Obesity
- Plain-language title
- Testing ALN-6222 in Adults With ObesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07624071, who can take part
- Record updated
- 12 November 2026